Health Condition 1: E785- Hyperlipidemia, unspecified
Conditions
Interventions
Intervention1: Medohara vati: 2 tablet 3 times a day for 2 months
Control Intervention1: Not applicable: Not applicable
Sponsors
Patanjali Research Institute Haridwar
Eligibility
Inclusion criteria
Inclusion criteria: Participant is not on a statin or other lipid-modifying therapy. Plasma levels >=200 mg/dL for TC, >=130 mg/dL for LDL-C, =150 mg/dL and (b) serum CRP >5 mg/dL.
Exclusion criteria
Exclusion criteria: o Female participant of reproductive potential. o Participant is pregnant, breastfeeding, or expecting to conceive during the study. o Participant has history of cancer within 5 years of study (except certain types of skin and cervical cancer). o Participant is a user of recreational or illicit drugs or has a recent history of drug and/or alcohol abuse. o Participant has donated or received blood within 8 weeks of study start or intends to give/receive blood during the study. o Participant consumes more than 3 alcoholic drinks per day or more than 14 alcoholic drinks per week. o Participant is currently experiencing menopausal hot flashes. o Participant currently engages in vigorous exercise or an aggressive diet regimen. o Participant is at high risk for heart conditions. o Participant has Type 1 or Type 2 diabetes mellitus. o Participant has poorly controlled cardiac arrhythmias. o Participant has a history of stroke or other hemorrhage. o Participant has poorly controlled high blood pressure. o Participant has a thyroid condition or other endocrine/metabolic disease that would affect serum lipids. o Participant has a disease of the kidney or liver. o Participant has an ulcer within 3 months of screening. o Participant is Human Immunodeficiency Virus (HIV) positive. o Participant is taking cyclical hormonal contraceptives or non-continuous hormone replacement therapy. o Participant is taking or has taken an Organic Anion Transporter (OAT1/3) inhibitor/substrate within 3 days of screening. o Participant has taken an anti-obesity medication within 3 months of screening. o Participant is taking coumarin. o Participant is taking Non-Steroidal Anti-inflammatory Drugs (NSAIDs) (acetaminophen and Cyclooxygenase-2 (COX-2) inhibitors are allowed). o Participant is taking more than 100 mg aspirin per day. o Participant is being treated with oral, intravenous, or injected corticosteroids or anabolic agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Cholesterol S. Triglyceride S.HDL S.LDL S.VLDLTimepoint: every month, Before treatmetnt, After cmpletion of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| BMITimepoint: every month for 2 months | — |
Countries
India
Contacts
Public ContactProf R B Sati
Main Campus, Uttarakhand Ayurved University
Outcome results
None listed